… this information to us, so that we are able to make proper arrangements to support you during an interview. We … you send us your contact details, resume, *references (*optional) by mail or online submission form; We also … current and former employers; b) any references you have optionally provided; c) third parties who recruit on our …
… company was founded in 2012, our mission has been to help people living with rare diseases that currently have no treatment options. This remains an important focus of our company … Read more about our Founding story . Patient-focused drug development Patient-focused drug development In order to …
… pdf , 1.54 MB Download link RNA Editing Summit (2024) Developing Axiomer RNA Editing Technology Towards Clinical Development pdf , 2.83 MB External link ASGCT (2024) … to Address Liver Originated Disorders Internal link OPT Congress (2023) Gerard Platenburg, Therapeutic potential …
… ways, including via the Whistleblower Hotline which is operated by a third party SpeakUp and always available. The … confidential communication, and also allows for (optional) anonymous reporting. Report submitted to the … who will decide on further steps of investigation, as appropriate. Whistleblower Hotline reports may be made via …
… and Company. The partnership focuses on the discovery, development, and commercialization of potential new medicines … genetic disorders. The ongoing collaboration uses ProQR’s proprietary Axiomer™ RNA editing platform to progress … additional targets, along with an option for Lilly to opt in for more. Lilly is a leader in RNA therapeutics, and …
… was diagnosed with a rare disease, he started ProQR to develop RNA therapies for rare diseases. Before founding … background in RNA modulation and orphan drug discovery and development and is currently in charge of our R&D. Gerard has … has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for …
… be themselves, feel comfortable in our workplace, and help develop our next generation of RNA medicines. Being yourself … join us at ProQR couldn’t be easier. If you are sending an open application or have found a vacancy that catches your … forms and, at your discretion, please include any optional information that will help us get to know you …
2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed steadily. The team expects to start a first clinical trial this year.
… and Drug Substance (DS) manufacturing team to lead process optimization efforts and supervise/lead tech transfer, and … are a true believer of the value of a workforce in which people from diverse backgrounds are encouraged to develop themselves, personally and professionally. We believe …
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
